Kornimate/medical-research-clean huggingface dataset:
standardized infant neurodevelopmental assessment (sinda) in 0-24 months age in turkey

Conditions: Infant, Premature, Diseases; Motor Development

Summary: this study aims to assess turkish validity and reliability of standardized infant neurodevelopmental assessment and to spread its use for evaluation in early rehabilitation in our country.

there are developments in the field of diagnosing children with a high risk of developmental disorders such as cerebral palsy (cp), mental problems and autism spectrum disorder in infancy. in particular, in infants experiencing the onset of extrauterine life in the neonatal intensive care unit, the combination of neonatal neuroimaging along with the assessment of general movements results in a highly accurate prediction of cp . a clinical tool often used in predictions is a neurological examination. various standard variants are available, such as the hammersmith infant neurological examination (hine), alberta infant motor scale (aims). the neurological scale of sinda is designed as a screening tool as follows: (1) in the first year of life after the neonatal period, that is, in the corrected age range of 6 weeks to 12 months; (2) covers all infant neurological areas; (3) it is standardized, that is, it has a set of items and criteria identical to that age range; (4) results in a score that is largely independent of the baby's age; (5) general pediatricians are easy to use and take about 10 minutes to do (including recording scores); (6) contains a substantial part of items assessing the quality of spontaneous movements; and (7) helps predict developmental outcome .this study aims to assess turkish validity and reliability of standardized infant neurodevelopmental assessment and to spread its use for evaluation in early rehabilitation in our country.

Eligibility criteria:
inclusion criteria: * at-risk infants * discharged from neonatal intensive care unit; * age between 0 - 24 months old (corrected age for premature infants); * having a family acceptance for the participation exclusion criteria: * having congenital anomalies, * musculoskeletal disorders, * cyanotic congenital heart disease and * mechanical dependency

Keywords: infant validty neurologic examination motor development
adult primary insomnia polysomnographic study (0928-004)(completed)

Conditions: Primary Insomnia

Summary: the purpose of the study is to test the safety and effectiveness of the investigational drug on insomnia.


Eligibility criteria:
inclusion criteria: * adult patients with a diagnosis of primary insomnia and in good physical and mental health exclusion criteria: * adult patients with other medical , neurological and sleep disorders
micro-rna expression profiles in high risk prostate cancer

Conditions: Prostate Cancer; Radical Prostatectomy

Summary: the purpose of this study is to determine whether specific micro-rna expression profiles are related to prostate cancer outcome.


Eligibility criteria:
inclusion criteria: patients with clinically localised high risk prostate cancer (ct\>2, bx gs \>7, psa \>20 ng/ml) scheduled for radical prostatectomy. exclusion criteria: non high risk prostate cancer

Keywords: high-risk prostate cancer radical prostatectomy micro-rna
efficacy and safety of calcipotriol plus betamethasone gel in the treatment of scalp psoriasis

Conditions: Psoriasis of Scalp

Summary: the purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) gel is safe and more effective than betamethasone 0.5 mg/g (as dipropionate) in the gel vehicle, calcipotriol 50 mcg/g in the gel vehicle or the gel vehicle used alone in patients with scalp psoriasis. the primary outcome is the proportion of patients with absence of disease or very mild disease after 8 weeks of treatment.


Eligibility criteria:
main inclusion criteria: * scalp psoriasis amenable to topical treatment * psoriasis vulgaris on trunk and/or limbs * extent of scalp psoriasis involving more than 10% of the total scalp area * disease severity on the scalp graded as mild or worse by the investigator * consenting out-patients of 18 years or above main exclusion criteria: * puva or grenz ray therapy within 4 weeks prior to randomisation * uvb therapy within 2 weeks prior to randomisation * systematic treatment with biological therapies, with a possible effect on scalp psoriasis within 6 months prior to randomisation * systemic treatment with all other therapies than biologicals, with a possible effect on scalp psoriasis (e.g., corticosteroids, vitamin d analogues, retinoids, immunosuppressants) within 4 weeks prior to randomisation * any topical treatment of the scalp (except for medicated shampoos and emollients) within 2 weeks prior to randomisation * topical treatment of the face, trunk and/or limbs with very potent who group iv corticosteroids within 2 weeks prior to randomisation * current diagnosis of erythrodermic, exfoliative or pustular psoriasis
the role of netrin -1 in acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: in our study, netrin -1; we found that patients with acs increased at the time of admission, decreased timi 3 flow after angiography, and higher risk groups in high risk groups such as timi and grace were found to have higher netrin-1 levels.


Eligibility criteria:
inclusion criteria: * patients over the age of 18 * diagnose acs * patients undergoing angiography exclusion criteria: * cve history * neurological disease * pregnancy and lactation * liver failure * diagnosed malignity * use of anticonvulsant and nephrotoxic medication * chronic kidney disease * not having angiography * developing acute renal failure after angiography * patients who rejected to participate were excluded.

Keywords: netrin-1 acs reperfuzion
adherence & health outcome differences amongst hiv infected patients prescribed haart

Conditions: Acquired Immunodeficiency Syndrome; Human Immunodeficiency Virus Type

Summary: this study is designed to see how hiv infected patients perform when taking a single fixed dose hiv medication compared to a regimen with multiple tablets. the study is also going to be looking at the differences in complications between the two groups.

this is a phase iv retrospective chart review of hiv infected patients in a private infectious disease practice in west palm beach, fl. this chart review will assign patients into one of two groups based on their antiretroviral regimen: single tablet regimen (str) versus multi tablet regimen (mtr). up to 650 patient charts will be reviewed but only about 500 patients are needed for statistical analysis. the primary objective is to look at the proportion of patients with an adherence rate greater than or equal to 95% in subjects prescribed str versus a mtr. secondary objectives: * differences in emergency room visits, hospitalization and readmission in patients taking a str vs. a mtr * proportion of patients with hiv viral load less than 50copies/microliter * incidence of new onset or worsening hyperlipidemia in patients taking a str versus a mtr * incidence of acute renal insufficiency * compare the absolute cd4 number increase between a str and a mtr * compare monthly copay amounts in patients taking a str versus a mtr * identify the incidence of opportunistic infections in patients taking a str versus a mtr

Eligibility criteria:
inclusion criteria: * male or female (gender at birth), age 18 years or older * documented hiv-1 infection by western blot or hiv viral load * prescribed antiretroviral therapy, either str (single tablet regime) or mtr (multi tablet regimen) for at least 6 months * patients should have a minimum of 3 office visits exclusion criteria: * patients who were evaluated in the hospital but never came to the clinic

Keywords: hiv/aids
myocardial ischemia in non-obstructive coronary artery disease

Conditions: Coronary Atherosclerosis; Myocardial Ischemia

Summary: the aim of the study is to assess presence of myocardial ischemia by contrast stress echocardiography in patients with symptomatic non-obstructive coronary artery disease (cad) by ct-coronary angiography, and the clinical, vascular, biochemical and genetic markers of myocardial ischemia in such patients.

non-obstructive coronary artery disease (cad) is particularly common in women and associated with reduced quality of life and increased cardiovascular morbidity and mortality. the project will recruit patients with angina pectoris and non-obstructive cad by ct- coronary angiography for further imaging with contrast stress echocardiography for diagnosis of myocardial ischemia. better characterization of patients with symptomatic non-obstructive cad due to myocardial ischemia will be done by vascular assessment by tonometry, biochemical and genetic markers as well as quality of life questionnaire. this interdisciplinary project is expected to add new knowledge to the impact of multimodality cardiac imaging in improving diagnosis in patients with symptomatic non-obstructive cad.

Eligibility criteria:
inclusion criteria: * age \>30 years * chest pain and or functional dyspnoea with a duration \> 6 months * non-obstructive coronary artery disease detected by ct coronary angiography exclusion criteria: * significant coronary artery stenosis or normal coronary arteries by ct coronary angiography * unstable coronary artery disease * significant valvular heart disease * mechanical valve prosthesis * significant arrhythmia * severly reduced pulmonary function (gold 3-4) * known allergy to ultrasound contrast agents * pregnancy * inability to sign informed consent to participate * other severe disease

Keywords: ct coronary angiography contrast stress echocardiography arterial stiffness quality of life biochemical and genetic markers
chronic hepatitis b virus clinical epidemiology in a representative sample of zambian adults

Conditions: HBV; Alcoholic Hepatitis; Liver Fibroses

Summary: the purpose of this study is to recruit a random and representative sample of individuals within several zambian communities for markers of hepatitis b virus (hbv) and to characterize chronic hbv infection and indications for treatment.

the zambian ministry of health (moh) considers viral hepatitis a significant public health threat; however, there are limited representative data on hbv burden, risk factors, clinical significance, and interaction with co-infections and co-morbidities that are common in zambia. in collaboration with the central statistical office, moh, and centers for disease control and prevention, the zambia population-based hiv impact assessment (zamphia) will be testing a representative sample of zambians across all 10 provinces for hbv infection. this is an important first step toward understanding the burden of disease and its distribution across the country. the goal of this study is to generate further information for consumption by local and regional health policymakers. the investigators will research the epidemiologic risk factors for lifetime and current hbv infection, characterize clinical features of chronic hiv in zambia, and describe key virological, serological, and comorbid factors that are critical to developing the best policies for hbv control in zambia.

Eligibility criteria:
inclusion criteria: * part 1: 18 years or older, current residence in selected household * part 2: participant in part 1 of the study, hbsag-positive by rapid point-of-care test exclusion criteria: * part 1: unable to provide informed consent * part 2: unwilling to travel to a hospital in their province
high-dose methotrexate (mtx) for adult acute lymphoblastic leukemia (all)

Conditions: Lymphoblastic Leukemia, Acute

Summary: the purpose of this study is to investigate the clinical efficacy of high-dose methotrexate consolidation therapy for adult patients with bcr-abl-negative all.

although the multi-agent chemotherapies in current use produce complete remission for a majority of patients with acute lymphoblastic leukemia (all), the prognosis for adult all remains discouraging due to a high incidence of relapse. optimal post-remission therapy, therefore, has been a matter of vital concern. in some pediatric all studies, the use of high-dose methotrexate (mtx) as a consolidation therapy, has been shown to improve outcome, however, there has been no randomized controlled trials to test its clinical efficacy in adult all. with this concern, the japan adult leukemia study group (jalsg) has planned a prospective randomized controlled trial comparing high-dose mtx and intermediate-dose mtx for all patients who are negative for bcr-abl. those who are positive for bcr-abl can participate in a separate protocol.

Eligibility criteria:
inclusion criteria: * previously untreated bcr-abl-negative all * age between 25 and 64 years * performance status between 0 and 3 (ecog criteria) * adequate functioning of the liver (serum bilirubin level \< 2.0 mg/dl); kidneys (serum creatinine level \< 2.0 mg/dl); and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs). * written informed consent to participate in the trial exclusion criteria: * uncontrolled active infection * another severe and/or life-threatening disease * positive for hiv antibody and/or hepatitis b surface (hbs) antigen tests * another primary malignancy which is clinically active and/or requires medical interventions * pregnant and/or lactating women * past history of renal failure

Keywords: acute lymphoblastic leukemia newly diagnosed bcr-abl-negative
effects of slow breathing on blood pressure and autonomic function

Conditions: Hypertension

Summary: hypertension is a chronic disease that affects about 23% of the brazilian population. the treatment of hypertension by pharmacological intervention is efficacious, but has side effects and significant costs. techniques that reduce the respiratory rate are shown as a effective non-pharmacological treatment in controlling blood pressure. evidence has shown that a slow and deep breathing rate, around 10 breaths per minute or less, significantly reduces blood pressure. however, the physiological mechanisms involved in blood pressure decrease due to decreased respiratory rate are not yet known. therefore the goals of this study will evaluate the chronic effect of breathing exercise guided on office and 24 hours blood pressure and analyse the chronic effect of breathing exercise guided over the autonomic function in hypertensive patients in stages 1 and 2.


Eligibility criteria:
inclusion criteria: * hypertensive patients with or without use of antihypertensive drug therapy with office systolic blood pressure between 140 and 179 mmhg and / or office diastolic between 90 and 109mmhg). * adults over 18 years. * both genders. exclusion criteria: * use of medications that alter sympathetic nerve activity (beta blockers and / or sympatholytics). * use of three or more classes of antihypertensive drugs * secondary hypertension * chronic respiratory disease * diabetes mellitus. * chronic kidney disease with clearance creatinine \<60 ml/min * congestive heart failure * coronary disease * pregnant * bmi \> 30 kg/m2

Keywords: hypertension device-guided breathing autonomic function resperate
inflammatory cardiomyopathy baseline cohort (sfb/tr19)

Conditions: Cardiomyopathies; Heart Failure

Summary: cohort of cardiomyopathy patients (suspected or validated inflammatory cardiomyopathy) recruited at baseline by the sfb-tr19 project. standardized protocols used for the assessment of medical history and examinations, laboratory biomarkers, and the collection of various biosamples for biobanking purposes.


Eligibility criteria:
inclusion criteria: * suspected inflammatory cardiomyopathy at baseline exclusion criteria: * none

Keywords: heart failure cardiomyopathies myocarditis
esomeprazole for treatment of gerd in pediatric patients

Conditions: Gastroesophageal Reflux Disease (GERD); Erosive Esophagitis; Non-erosive Esophagitis

Summary: to look at the safety and improvement in symptoms of a once a day dosing of esomeprazole in children 1 to 11 years old with inflammation of their esophagus or food pipe ("esophagitis") caused by gastroesophageal reflux disease (gerd) and diagnosed by endoscopy. to verify the healing of the esophageal inflammation if the endoscopy reveals cuts in the lining of the food pipe. to collect information that will describe the psychological, social, and economic effects on the primary caregiver of raising children ages 1 to 5 years old with gerd.


Eligibility criteria:
inclusion criteria: * patients' parents/guardians must provide written informed consent prior to the execution of any study-related procedures. * patients who are able to comprehend their involvement in a clinical study, including risks and benefits, (typically ≥6 years of age) must have assent documented by study personnel prior to any study-related procedures. * patients must be diagnosed with endoscopically proven gerd by the investigator during the screening period or have a previous (within 2 weeks prior to visit 1) diagnosis of erosive esophagitis by endoscopy and are candidates for ppi therapy. exclusion criteria: * patients who have used a proton pump inhibitor within 14 days prior to randomization, including over-the-counter omeprazole. * patients who have used any prescription or over-the-counter (otc) treatment (other than proton pump inhibitors) for symptoms of gerd, such as histamine 2 receptor antagonists or prokinetics, within 72 hours prior to randomization. * patients with a known hypersensitivity, allergy, or intolerance to any component of esomeprazole or omeprazole.
unna boots for ankle fracture swelling

Conditions: Ankle Fractures

Summary: this study will evaluate the difference in soft tissue swelling prior to surgery and wound complications after surgery between unna boot application versus standard splint application. an unna boot is an extra zinc covered wrap around your leg followed by standard splint application (cotton dressing, plaster, then soft dressing). prior to surgery the participant's swelling will be measured and compared to the standard splint application group. after surgery, the participant will be monitored for wound complications, pain, and range of motion.

the purpose of this study is to compare preoperative swelling and frequency of wound complications in ankle fractures through standard splint and an unna boot compressive dressing with a splint. quantitative and qualitative measurements will be analyzed to compare edema and wound complications. secondary goals are to evaluate the quantitative differences in ankle range of motion and visual analogue scale (vas) pain scores. the hypothesis of this proposed study is that there will be less soft tissue swelling and wound complications with the use of an unna boot when compared to the standard splint. the investigators also hypothesize that there will be improved ankle range of motion and visual analogue scale (vas) pain scores with the use of an unna boot when compared to a standard splint. participants will be randomized to either the standard splint or an unna boot and quantitative and qualitative measures will be collected. this data could change the practice for preoperative management of soft tissue swelling following ankle fractures.

Eligibility criteria:
inclusion criteria: * acute ankle fracture exclusion criteria: * low energy ankle fracture * open ankle fracture * unwillingness to participate * allergy to zinc * revision surgery
effect of ramosetron on bowel motility after colorectal resection

Conditions: Postoperative Nausea and Vomiting

Summary: ramosetron is effective in preventing postoperative nausea and vomiting. several studies reported that ramosetron is also effective treatment diarrhea-predominant irritable bowel syndrome. the investigators examine the effect of ramosetron used for preventing postoperative nausea and vomiting on bowel motility.

ramosetron, a new potent and long-acting selective 5-ht3 receptor antagonist, is effective for preventing postoperative nausea and vomiting. also several studies reported that ramosetron is effective treatment of irritable bowel syndrome because it inhibits the accelerated colonic transit, abnormal colonic water transport, defecation abnormality, and the lowered colonic perceptual threshold by corticotrophin-releasing hormone. there is no study about the effect of ramosetron used for preventing postoperative nausea and vomiting on postoperative bowel motility. in this study, the investigators examine the effect of ramosetron on postoperative bowel motility.

Eligibility criteria:
inclusion criteria: * 20-70 yr of age, * asa i or ii, * scheduled for laparoscopic colorectal surgery exclusion criteria: * antiemetic use within 24hr prior to surgery * steroid use within 24hr prior to surgery or 48hr after surgery * insulin dependent dm * cardiovascular or pulmonary disease * renal or hepatic insufficiency * bmi \>=35kg/m2 * pregnancy
buprenorphine/naloxone treatment for opioid dependence-experiment i(2) - 2

Conditions: Heroin Dependence; Opioid-Related Disorders

Summary: the purpose of this study is to compare the clinical efficacy of daily vs. 3-day (mwf) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in which take-home doses are given on intervening days.

mon/wed/fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as daily dosing and is preferred by patients to daily dosing. multiple doses of the combination tablet (e.g. 16mg, 24mg) are well tolerated by patients. a 3 day schedule with take-outs is as effective as a 3-day schedule in which all medication is ingested at the clinic

Eligibility criteria:
inclusion criteria: individual must be currently dependent and meet fda criteria for narcotic maintenance treatment. co-morbid substance abuse or dependence disorders may also be present. individuals must be healthy despite drug dependency. exclusion criteria: individuals with evidence of an active diagnostic and statistical manual of mental disorders (dsm-iv) axis i psychiatric disorder (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Keywords: drug dependence
evaluating the effectiveness of incentive spirometry

Conditions: Dyspnea; Respiratory Rate; Oxygen Saturation; Oxygen Requirements; FEV1; FVC; Atelectasis; Pneumonia; Re-intubation; Hospital Length of Stay; Nursing Workload; Incentive Spirometry

Summary: post-operative pulmonary complications (ppcs) have a major impact on patients and healthcare expenses. the goal of perioperative respiratory therapy is to improve airway clearance, increase lung volume, and mitigate atelectasis. incentive spirometers (is) are ubiquitously used to prevent atelectasis and ppcs-implementation of which requires substantial provider time and healthcare expenses. however, meta-analyses have demonstrated that the effectiveness of iss is unclear due to poor patient compliance in past studies. the goal of this investigation is evaluate the effectiveness of is on post-operative clinical outcomes. the aims of this investigation are to evaluate 1) if is use compliance can be improved by adding a use-recording patient reminder alarm, and 2) the clinical outcomes of the more compliant is users vs. the less-compliant is users.


Eligibility criteria:
inclusion criteria: * undergoes any cardiothoracic surgery * is transferred to the cardiothoracic surgery intermediate (step-down) unit at rhode island hospital * already prescribed an incentive spirometer as standard-of-care * followed by any healthcare provider * ability to sign informed consent and comply with all study procedures including follow-up for up to 1 year exclusion criteria: * \<18 years of age * vulnerable population who in the judgment of the investigator is unable to give informed consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy.